Zacks Investment Research·14h ago
TG Therapeutics Begins Phase II Study With Briumvi in SchizophreniaTGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
TG Therapeutics, Inc.(TGTX)Earnings, Financials & Key Ratios
TGTX•NASDAQ
$53.52
19.3× P/E·Price updated Jul 7, 2026
AboutTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.Show more
- Revenue$616M+87.3%
- EBITDA$124M+192.8%
- Net Income$447M+1812.4%
- EPS (Diluted)2.77+1746.7%
- Gross Margin83.66%-5.3%
- EBITDA Margin20.05%+56.3%
- Operating Margin20.01%+57.0%
- Net Margin72.56%+920.9%
- ROE102.75%+741.2%
TGTX Price & Volume
TG Therapeutics, Inc. (TGTX) stock price & volume — 10-year historical chart
Loading chart...
Briumvi Commercial Scaling Masks Persistent Cash Volatility
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Expanding
Profitability:Moderate
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Single asset revenue dependency
Key Thesis Takeaways
- TG Therapeutics is currently navigating a critical commercial inflection point as Briumvi adoption drives a 69.6% year-over-year revenue growth rate as of 2026Q1.
- However, the company's reliance on intangible assets and a $1.1 billion accumulated deficit suggests that long-term value creation remains highly speculative.
- Investors should monitor the disconnect between accounting profits and cash generation, particularly given the $69.8 million working capital drain observed in the most recent quarter.
Verdict Logic
while the 69.6% revenue growth rate is impressive, the company's negative 8.8% free cash flow margin and $100 million in share repurchases during a period of negative operating cash flow suggest significant risks to long-term liquidity.
TGTX Growth Metrics
TG Therapeutics, Inc. (TGTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years129.45%
5 Years426.73%
3 Years504.86%
TTM81.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1079.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1070.69%
Return on Capital
10 Years-114.01%
5 Years-27.68%
3 Years12.86%
Last Year17.66%
TGTX Recent Earnings
TG Therapeutics, Inc. (TGTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.17-26.1%
$0.23
Rev
$205M+2.3%
$200M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.14-60.0%
$0.35
Rev
$193M+0.4%
$192M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$2.43+912.5%
$0.24
Rev
$162M-16.6%
$194M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.17-46.9%
$0.32
Rev
$141M-3.5%
$146M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.17vs $0.23-26.1% | $205Mvs $200M+2.3% |
| Q1 2026 | Feb 26, 2026 | $0.14vs $0.35-60.0% | $193Mvs $192M+0.4% |
| Q4 2025 | Nov 3, 2025 | $2.43vs $0.24+912.5% | $162Mvs $194M-16.6% |
| Q3 2025 | Aug 4, 2025 | $0.17vs $0.32-46.9% | $141Mvs $146M-3.5% |
Based on last 12 quarters of dataView full earnings history →
Latest TGTX News
Recent stock market news and headlines for TG Therapeutics, Inc. (TGTX)
GlobeNewsWire·1 day ago
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant SchizophreniaPhase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients
Zacks Investment Research·4 days ago
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
Benzinga·Jun 18, 2026
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.
Investors Business Daily·Jun 17, 2026
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And ClimbingTG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.
Peers Comparison
Key metrics vs top competitors for TG Therapeutics, Inc. (TGTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $53.52 | $8.19B | 19.32 | 87.32% | 72.56% | 102.75% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $522.25 | $132.84B | 34.09 | 9.57% | 35.4% | 23.93% | — |
Compare TGTX vs Peers
TG Therapeutics, Inc. (TGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TGTX SEC Filings & Documents
TG Therapeutics, Inc. (TGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 26, 2026·SEC
10-K Annual Reports
510-Q Quarterly Reports
6Get notified when TGTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TGTX Frequently Asked Questions
TG Therapeutics, Inc. (TGTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is TG Therapeutics, Inc.'s revenue?
TG Therapeutics, Inc. (TGTX) reported $700.3M in revenue for fiscal year 2025. This represents a 700249% increase from $0.1M in 1996.
How fast is TG Therapeutics, Inc. growing?
TG Therapeutics, Inc. (TGTX) grew revenue by 87.3% over the past year. This is strong growth.
Is TGTX profitable?
Yes, TG Therapeutics, Inc. (TGTX) is profitable, generating $461.9M in net income for fiscal year 2025 (72.6% net margin).
Dividend & Returns
What is TGTX's return on equity?
TG Therapeutics, Inc. (TGTX) has a return on equity (ROE) of 102.8%. This is excellent, indicating efficient use of shareholder capital.
What is TG Therapeutics, Inc.'s free cash flow?
TG Therapeutics, Inc. (TGTX) had negative free cash flow of $14.2M in fiscal year 2025, likely due to heavy capital investments.